5Verma S,Li SH,Badiwala MV,et al.Endothelin antagonism and interleukin-6 inhibition attenuate the protherogentic effects of C-reative protein[J].Circulation,2002,105(16):1 890-1 896.
6Subodh V,Chao-Hung W,Shu-Hong L,et al.C-reative protein attenuates nitric oxide production and inhibits angiogenesis[J].Circulation,2002,106(8):913-919.
7Ahmadi K,Wilson C,Tiwana H,Binder A,et al.Antibodies to Klebsiella pheumoniae lipopolysacchride in patients wita ankylosing spondylitis[J].Br J Rheumatol,1998,37(12):1 330-1 333.
8Garrett S,Jenkinson T,Kennedy LG,et al.A new approach to defining disease status in ankylosing spondylitis:the Bath Ankylosing Spondylitis Disease Activity Index[J].J Rheumatol,1994,21(12):2 286-2 291.
9Spoorenberg A,van der Heijde D,de Klerk E,et al.Relative value of erythrocyte sedimentation rate and C-reative protein in assessment of disease activity in ankylosing spondylitis[J].J Rheumatol,1999,26(4):980-984.
5Montes T, Tortajada A, Morgan BP, et al. Functional basis of protection against age - related macular degeneration conferred by a common pol- ymorphism in complement factor B [ J]. Proc Natl Sci USA ,2009,106 (11) :4366 -4371.
6Gou SJ, Yuan J, Chen M, et aL Circulating complement activation in patients with anti - neutrophil cytoplasmic antibody - associated vascu- litis[ J]. Kidney Int,2013,83(1) :129 - 137.
7Watanabe H, Garnier G, Circolo A,et al. Modulation of renal disease in MRL/Ipr mice genetically deficient in the alternative complement pathway factor B [ J ]. J Immunol,2000,164 (2) : 786 - 794.
